Literature DB >> 25991382

Changes in lower urinary tract symptoms and quality of life after salvage radiotherapy for biochemical recurrence of prostate cancer.

Makito Miyake1, Nobumichi Tanaka2, Isao Asakawa3, Yoshihiro Tatsumi4, Yasushi Nakai1, Satoshi Anai1, Kazumasa Torimoto1, Katsuya Aoki1, Tatsuo Yoneda1, Masatoshi Hasegawa3, Noboru Konishi5, Kiyohide Fujimoto1.   

Abstract

BACKGROUND AND
PURPOSE: The aim of this study was to evaluate chronologic changes in lower urinary tract symptoms (LUTS), health-related (HR) quality of life (QOL), and disease-specific QOL during the first 12 months after salvage radiotherapy (SRT) for biochemical recurrence of prostate cancer in patients who underwent radical prostatectomy.
MATERIALS AND METHODS: In 81 patients who received SRT (70 Gy/35fr/7 weeks), International Prostate Symptom Score (IPSS), 36-Item Short Form scores, and UCLA-Prostate Cancer Index (UCLA-PCI) were recorded before, during, and immediately after SRT, and 1-12 months after the completion of SRT.
RESULTS: The total IPSS and storage symptom-related sum were significantly increased following initiation of SRT, and returned to the baseline 6 months after SRT. For three of eight domains of HRQOL, and the physical component summary score showed transient deterioration in the period between completion of SRT and 1 month following SRT. The UCLA-PCI for urinary function/bother and bowel function/bother was affected until 1-6 months after SRT.
CONCLUSIONS: This is the first report to concurrently evaluate detailed chronologic changes in LUTS and QOL in patients who received SRT. Knowledge of changes in LUTS and QOL outcomes associated with SRT may influence treatment recommendations and enable patients to make better-informed decisions.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Disease-specific quality of life; Health-related quality of life; International Prostate Symptom Score; Prostate cancer; SF-36; Salvage radiotherapy

Mesh:

Year:  2015        PMID: 25991382     DOI: 10.1016/j.radonc.2015.04.026

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  6 in total

1.  Functional and oncological outcomes of salvage external beam radiotherapy following robot-assisted radical prostatectomy in a Canadian cohort.

Authors:  Khaled Ajib; Marc Zanaty; Mansour Alnazari; Emad Rajih; Pierre-Alain Hueber; Mila Mansour; Roger Valdivieso; Cristina Negrean; Pierre I Karakiewicz; Daniel Taussky; Guila Delouya; Assaad El-Hakim; Kevin C Zorn
Journal:  Can Urol Assoc J       Date:  2017-12-01       Impact factor: 1.862

2.  Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute.

Authors:  Makito Miyake; Nobumichi Tanaka; Isao Asakawa; Shunta Hori; Yosuke Morizawa; Yoshihiro Tatsumi; Yasushi Nakai; Takeshi Inoue; Satoshi Anai; Kazumasa Torimoto; Katsuya Aoki; Masatoshi Hasegawa; Tomomi Fujii; Noboru Konishi; Kiyohide Fujimoto
Journal:  BMC Urol       Date:  2017-08-14       Impact factor: 2.264

3.  Oncological outcome, complications, lower urinary tract symptoms, and health-related quality of life after low-dose-rate salvage brachytherapy for recurrent prostate cancer following primary radiotherapy: a report of 8 cases.

Authors:  Makito Miyake; Nobumichi Tanaka; Isao Asakawa; Shunta Hori; Yosuke Morizawa; Yasushi Nakai; Satoshi Anai; Kazumasa Torimoto; Katsuya Aoki; Nagaaki Marugami; Masatoshi Hasegawa; Tomomi Fujii; Noboru Konishi; Kiyohide Fujimoto
Journal:  J Contemp Brachytherapy       Date:  2017-07-27

4.  Quality of life worsened the most severely in patients immediately after intensity-modulated radiotherapy for prostate cancer.

Authors:  Yasushi Nakai; Nobumichi Tanaka; Satoshi Anai; Makito Miyake; Isao Asakawa; Yosuke Morizawa; Shunta Hori; Kazumasa Torimoto; Tomomi Fujii; Masatoshi Hasegawa; Kiyohide Fujimoto
Journal:  Res Rep Urol       Date:  2018-10-23

5.  Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells.

Authors:  Xiaofang Wang; Wenjuan Zhang; Zi Yan; Yupei Liang; Lihui Li; Xiaoli Yu; Yan Feng; Shen Fu; Yanmei Zhang; Hu Zhao; Jinha Yu; Lak Shin Jeong; Xiaomao Guo; Lijun Jia
Journal:  Oncotarget       Date:  2016-06-21

Review 6.  Data-driven translational prostate cancer research: from biomarker discovery to clinical decision.

Authors:  Yuxin Lin; Xiaojun Zhao; Zhijun Miao; Zhixin Ling; Xuedong Wei; Jinxian Pu; Jianquan Hou; Bairong Shen
Journal:  J Transl Med       Date:  2020-03-07       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.